1. Home
  2. SJT vs PLYX Comparison

SJT vs PLYX Comparison

Compare SJT & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

N/A

Current Price

$4.81

Market Cap

139.8M

Sector

Energy

ML Signal

N/A

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$1.51

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SJT
PLYX
Founded
1980
2014
Country
United States
United States
Employees
495
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.8M
112.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
SJT
PLYX
Price
$4.81
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.50
AVG Volume (30 Days)
★ 256.8K
17.5K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.53
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$1.56
52 Week High
$6.27
$10.93

Technical Indicators

Market Signals
Indicator
SJT
PLYX
Relative Strength Index (RSI) 66.00 32.56
Support Level $2.72 N/A
Resistance Level $5.31 $2.18
Average True Range (ATR) 0.41 0.10
MACD 0.15 -0.02
Stochastic Oscillator 84.75 2.27

Price Performance

Historical Comparison
SJT
PLYX

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: